Werewolf Therapeutics, Inc. (HOWL): who owns it and who trades it
As of Nov 16, 2026, HOWL insiders reported 105 open-market sales worth $3.9M and no purchases in the last 12 months, with 76% of the sale value made under pre-set 10b5-1 plans. The largest seller was Luke Evnin (Director), with $2.3M. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Werewolf Therapeutics
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Insider trades
In the last 12 months, HOWL insiders reported $0 of open-market purchases and $3.9M of sales. 76% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jul 7, 2026 | Luke Evnin | Director | Sale plan | 107,429 | $0.31 | $33.3K | Form 4 |
| Jul 6, 2026 | Luke Evnin | Director | Sale plan | 35,770 | $0.32 | $11.4K | Form 4 |
| Jun 29, 2026 | Luke Evnin | Director | Sale plan | 157,084 | $0.30 | $47.1K | Form 4 |
| Jun 17, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Sale | 389,216 | $0.35 | $136K | Form 4 |
| Jun 17, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Sale | 27,695 | $0.35 | $9.7K | Form 4 |
| Jun 16, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Sale | 139,686 | $0.37 | $51.7K | Form 4 |
| Jun 16, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Sale | 9,939 | $0.37 | $3.7K | Form 4 |
| Jun 15, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Sale | 120,216 | $0.39 | $46.9K | Form 4 |
| Jun 15, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Sale | 8,554 | $0.39 | $3.3K | Form 4 |
| Jun 12, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Sale | 159,119 | $0.40 | $63.6K | Form 4 |
| Jun 12, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Sale | 11,322 | $0.40 | $4.5K | Form 4 |
| Jun 11, 2026 | Peter Kolchinsky +3 | 10% owner | Sale | 17,437 | $0.38 | $6.6K | Form 4 |
| Jun 11, 2026 | Peter Kolchinsky +3 | 10% owner | Sale | 245,066 | $0.38 | $93.1K | Form 4 |
| Jun 10, 2026 | Peter Kolchinsky +3 | 10% owner | Sale | 42,872 | $0.37 | $15.9K | Form 4 |
| Jun 10, 2026 | Peter Kolchinsky +3 | 10% owner | Sale | 3,051 | $0.37 | $1.1K | Form 4 |
| Jun 9, 2026 | Peter Kolchinsky +3 | 10% owner | Sale | 345,235 | $0.37 | $128K | Form 4 |
| Jun 9, 2026 | Peter Kolchinsky +3 | 10% owner | Sale | 24,565 | $0.37 | $9.1K | Form 4 |
| Jun 9, 2026 | Luke Evnin | Director | Sale plan | 76,928 | $0.37 | $28.5K | Form 4 |
| Jun 8, 2026 | Luke Evnin | Director | Sale plan | 60,547 | $0.40 | $24.2K | Form 4 |
| Jun 5, 2026 | Luke Evnin | Director | Sale plan | 24,946 | $0.40 | $10K | Form 4 |
| Jun 4, 2026 | Luke Evnin | Director | Sale plan | 20,072 | $0.44 | $8.8K | Form 4 |
| Jun 3, 2026 | Luke Evnin | Director | Sale plan | 29,749 | $0.42 | $12.5K | Form 4 |
| Jun 2, 2026 | Luke Evnin | Director | Sale plan | 29,595 | $0.45 | $13.3K | Form 4 |
| Jun 1, 2026 | Luke Evnin | Director | Sale plan | 80,459 | $0.47 | $37.8K | Form 4 |
| May 29, 2026 | Luke Evnin | Director | Sale plan | 32,556 | $0.45 | $14.7K | Form 4 |
| May 28, 2026 | Luke Evnin | Director | Sale plan | 27,698 | $0.46 | $12.7K | Form 4 |
| May 27, 2026 | Luke Evnin | Director | Sale plan | 80,852 | $0.48 | $38.8K | Form 4 |
| May 26, 2026 | Luke Evnin | Director | Sale plan | 67,950 | $0.47 | $31.9K | Form 4 |
| May 22, 2026 | Luke Evnin | Director | Sale plan | 87,425 | $0.45 | $39.3K | Form 4 |
| May 21, 2026 | Luke Evnin | Director | Sale plan | 36,387 | $0.42 | $15.3K | Form 4 |
| May 20, 2026 | Luke Evnin | Director | Sale plan | 85,895 | $0.43 | $36.9K | Form 4 |
| May 19, 2026 | Luke Evnin | Director | Sale plan | 62,970 | $0.45 | $28.3K | Form 4 |
| May 18, 2026 | Luke Evnin | Director | Sale plan | 22,184 | $0.50 | $11.1K | Form 4 |
| May 13, 2026 | Luke Evnin | Director | Sale plan | 44,679 | $0.54 | $24.1K | Form 4 |
| May 12, 2026 | Luke Evnin | Director | Sale plan | 67,885 | $0.64 | $43.4K | Form 4 |
| May 12, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Sale | 6,719 | $0.64 | $4.3K | Form 4 |
| May 12, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Sale | 94,432 | $0.64 | $60.4K | Form 4 |
| May 11, 2026 | Luke Evnin | Director | Sale plan | 33,948 | $0.67 | $22.7K | Form 4 |
| May 11, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Sale | 5,812 | $0.67 | $3.9K | Form 4 |
| May 11, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Sale | 81,678 | $0.67 | $54.7K | Form 4 |
| May 8, 2026 | Luke Evnin | Director | Sale plan | 305,741 | $0.70 | $214K | Form 4 |
| May 8, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Sale | 351,514 | $0.71 | $250K | Form 4 |
| May 8, 2026 | Ra Capital Management, L.P. +3 | 10% owner | Sale | 25,012 | $0.71 | $17.8K | Form 4 |
| May 7, 2026 | Luke Evnin | Director | Sale plan | 79,086 | $0.63 | $49.8K | Form 4 |
| May 6, 2026 | Luke Evnin | Director | Sale plan | 14,635 | $0.66 | $9.7K | Form 4 |
| May 5, 2026 | Luke Evnin | Director | Sale plan | 6,860 | $0.69 | $4.7K | Form 4 |
| May 4, 2026 | Luke Evnin | Director | Sale plan | 47,963 | $0.72 | $34.5K | Form 4 |
| May 1, 2026 | Luke Evnin | Director | Sale plan | 58,394 | $0.73 | $42.6K | Form 4 |
| Apr 30, 2026 | Luke Evnin | Director | Sale plan | 168,262 | $0.72 | $121K | Form 4 |
| Apr 29, 2026 | Luke Evnin | Director | Sale plan | 56,559 | $0.69 | $39K | Form 4 |
| Apr 28, 2026 | Luke Evnin | Director | Sale plan | 95,412 | $0.73 | $69.7K | Form 4 |
| Apr 27, 2026 | Luke Evnin | Director | Sale plan | 53,940 | $0.85 | $45.8K | Form 4 |
| Jan 16, 2026 | Luke Evnin | Director | Sale plan | 38,782 | $0.54 | $20.9K | Form 4 |
| Jan 15, 2026 | Luke Evnin | Director | Sale plan | 37,413 | $0.55 | $20.6K | Form 4 |
| Jan 14, 2026 | Luke Evnin | Director | Sale plan | 30,616 | $0.57 | $17.5K | Form 4 |
| Jan 13, 2026 | Luke Evnin | Director | Sale plan | 43,198 | $0.55 | $23.8K | Form 4 |
| Jan 12, 2026 | Luke Evnin | Director | Sale plan | 58,980 | $0.57 | $33.6K | Form 4 |
| Jan 9, 2026 | Luke Evnin | Director | Sale plan | 24,678 | $0.61 | $15.1K | Form 4 |
| Jan 8, 2026 | Luke Evnin | Director | Sale plan | 7,716 | $0.63 | $4.9K | Form 4 |
| Jan 7, 2026 | Luke Evnin | Director | Sale plan | 11,915 | $0.64 | $7.6K | Form 4 |
| Jan 6, 2026 | Luke Evnin | Director | Sale plan | 40,761 | $0.65 | $26.5K | Form 4 |
| Jan 5, 2026 | Luke Evnin | Director | Sale plan | 18,378 | $0.64 | $11.8K | Form 4 |
| Jan 2, 2026 | Luke Evnin | Director | Sale plan | 18,568 | $0.63 | $11.7K | Form 4 |
| Dec 31, 2025 | Luke Evnin | Director | Sale plan | 24,962 | $0.62 | $15.5K | Form 4 |
| Dec 30, 2025 | Luke Evnin | Director | Sale plan | 34,847 | $0.61 | $21.3K | Form 4 |
| Dec 29, 2025 | Luke Evnin | Director | Sale plan | 108,606 | $0.61 | $66.2K | Form 4 |
| Dec 26, 2025 | Luke Evnin | Director | Sale plan | 35,632 | $0.63 | $22.4K | Form 4 |
| Dec 24, 2025 | Luke Evnin | Director | Sale plan | 16,310 | $0.65 | $10.6K | Form 4 |
| Dec 23, 2025 | Luke Evnin | Director | Sale plan | 71,428 | $0.63 | $45K | Form 4 |
| Dec 22, 2025 | Luke Evnin | Director | Sale plan | 59,307 | $0.69 | $40.9K | Form 4 |
| Dec 17, 2025 | Luke Evnin | Director | Sale plan | 9,983 | $1.14 | $11.4K | Form 4 |
| Dec 16, 2025 | Luke Evnin | Director | Sale plan | 14,548 | $1.05 | $15.3K | Form 4 |
| Dec 15, 2025 | Luke Evnin | Director | Sale plan | 23,640 | $1.07 | $25.3K | Form 4 |
| Dec 12, 2025 | Luke Evnin | Director | Sale plan | 17,858 | $1.08 | $19.3K | Form 4 |
| Dec 11, 2025 | Luke Evnin | Director | Sale plan | 28,009 | $1.07 | $30K | Form 4 |
| Dec 10, 2025 | Luke Evnin | Director | Sale plan | 37,104 | $1.06 | $39.3K | Form 4 |
| Dec 9, 2025 | Luke Evnin | Director | Sale plan | 44,570 | $1.01 | $45K | Form 4 |
| Dec 8, 2025 | Luke Evnin | Director | Sale plan | 34,041 | $0.99 | $33.7K | Form 4 |
| Dec 5, 2025 | Luke Evnin | Director | Sale plan | 16,568 | $0.97 | $16.1K | Form 4 |
| Dec 4, 2025 | Luke Evnin | Director | Sale plan | 53,416 | $0.97 | $51.8K | Form 4 |
| Dec 4, 2025 | MPM BioVentures 2014 (B), L.P. +4 | Other | Sale plan | 83,230 | $0.97 | $80.7K | Form 4 |
| Dec 3, 2025 | Luke Evnin | Director | Sale plan | 36,726 | $0.87 | $32K | Form 4 |
| Dec 3, 2025 | MPM BioVentures 2014 (B), L.P. +4 | Other | Sale plan | 57,225 | $0.87 | $49.8K | Form 4 |
| Dec 2, 2025 | Luke Evnin | Director | Sale plan | 38,043 | $0.89 | $33.9K | Form 4 |
| Dec 2, 2025 | MPM BioVentures 2014 (B), L.P. +4 | Other | Sale plan | 59,277 | $0.89 | $52.8K | Form 4 |
| Dec 1, 2025 | Luke Evnin | Director | Sale plan | 39,096 | $0.94 | $36.8K | Form 4 |
| Dec 1, 2025 | MPM Asset Management Investors BV2014 LLC +4 | 10% owner | Sale plan | 60,917 | $0.94 | $57.3K | Form 4 |
| Nov 28, 2025 | Luke Evnin | Director | Sale plan | 13,014 | $0.99 | $12.9K | Form 4 |
| Nov 28, 2025 | MPM Asset Management Investors BV2014 LLC +4 | 10% owner | Sale plan | 20,277 | $0.99 | $20.1K | Form 4 |
| Nov 26, 2025 | Luke Evnin | Director | Sale plan | 38,978 | $0.98 | $38.2K | Form 4 |
| Nov 26, 2025 | MPM Asset Management Investors BV2014 LLC +4 | 10% owner | Sale plan | 60,733 | $0.98 | $59.5K | Form 4 |
| Nov 25, 2025 | Luke Evnin | Director | Sale plan | 27,297 | $0.92 | $25.1K | Form 4 |
| Nov 25, 2025 | MPM BioVentures 2014 GP LLC +4 | 10% owner | Sale plan | 42,533 | $0.92 | $39.1K | Form 4 |
| Nov 24, 2025 | Luke Evnin | Director | Sale plan | 56,992 | $0.98 | $55.9K | Form 4 |
| Nov 24, 2025 | MPM BioVentures 2014 GP LLC +4 | 10% owner | Sale plan | 88,802 | $0.98 | $87K | Form 4 |
| Nov 21, 2025 | Luke Evnin | Director | Sale plan | 41,287 | $0.83 | $34.3K | Form 4 |
| Nov 21, 2025 | MPM BioVentures 2014 GP LLC +4 | 10% owner | Sale plan | 64,331 | $0.83 | $53.4K | Form 4 |
| Nov 20, 2025 | Luke Evnin | Director | Sale plan | 26,411 | $0.89 | $23.5K | Form 4 |
| Nov 20, 2025 | MPM BioVentures 2014 LLC +4 | 10% owner | Sale plan | 41,152 | $0.89 | $36.6K | Form 4 |
| Nov 19, 2025 | Luke Evnin | Director | Sale plan | 42,566 | $0.94 | $40K | Form 4 |
Latest 100 of 105 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Luke Evnin | Director | – | $2.3M | Jul 7, 2026 |
| Ra Capital Management, L.P. | 10% owner | – | $710K | Jun 17, 2026 |
| Peter Kolchinsky | 10% owner | – | $254K | Jun 11, 2026 |
| MPM BioVentures 2014 LLC | 10% owner | – | $202K | Nov 20, 2025 |
| MPM BioVentures 2014 (B), L.P. | Other | – | $183K | Dec 4, 2025 |
| MPM BioVentures 2014 GP LLC | 10% owner | – | $180K | Nov 25, 2025 |
| MPM Asset Management Investors BV2014 LLC | 10% owner | – | $137K | Dec 1, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
HOWL short interest
Low short interest. 4.4% of HOWL shares are sold short: about 1 share in 23. Over the last 12 reports the number of shares short went up 219%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.13M HOWL shares were sold short, 4.4% of the shares outstanding, down 9.7% from the report before. At the average daily volume of 333,048 shares, buying them all back would take about 6.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.13M | 4.38% | -10% | 333,048 | 6.4 |
| Oct 15, 2026 | 2.36M | 4.85% | -6% | 462,233 | 5.1 |
| Sep 30, 2026 | 2.51M | 5.17% | +47% | 679,291 | 3.7 |
| Sep 15, 2026 | 1.71M | 3.51% | +2% | 897,287 | 1.9 |
| Aug 31, 2026 | 1.67M | 3.43% | +56% | 35.56M | 1.0 |
| Aug 14, 2026 | 1.07M | 2.20% | -3% | 288,605 | 3.7 |
| Jul 31, 2026 | 1.10M | 2.26% | +18% | 844,069 | 1.3 |
| Jul 15, 2026 | 934,340 | 1.92% | +10% | 910,820 | 1.0 |
| Jun 30, 2026 | 847,096 | 1.74% | -12% | 1.10M | 1.0 |
| Jun 15, 2026 | 964,624 | 1.98% | +2% | 495,747 | 1.9 |
| May 29, 2026 | 949,598 | 1.95% | +42% | 609,217 | 1.6 |
| May 15, 2026 | 667,626 | 1.37% | -8% | 678,465 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Werewolf Therapeutics company events
Werewolf Therapeutics filed 10 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership, listing). The latest was on Nov 9, 2026.
- Nov 9, 2026AnnouncementShared information with investors. Filing
- Aug 21, 2026AgreementWerewolf Therapeutics, Inc., a Delaware corporation, entered into an Agreement and Plan of Merger by and among Ambros Therapeutics, Inc., a Delaware corporation, Werewolf, and Wave Atlantis Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Werewolf. Filing
- Aug 20, 2026AgreementWerewolf Therapeutics, Inc. entered into an asset purchase agreement with EMD Serono Research & Development Institute Inc., pursuant to which, and subject to the terms and conditions thereof, the Company sold to EMD technology comprising (i) its pre-clinical INDUCER platform, including all patents… Filing
- Jul 31, 2026ResultsReleased financial results. Filing
- May 7, 2026ResultsReleased financial results. Filing
- Mar 27, 2026ResultsReleased financial results. Filing
- Feb 24, 2026AnnouncementWerewolf Therapeutics, Inc. issued a press release announcing that it plans to explore strategic alternatives and has engaged Piper Sandler & Co. as its exclusive financial advisor to assist in the strategic evaluation. Filing
- Feb 13, 2026LeadershipDeparture of Certain Officers As part of the Reduction, on February 9, 2026, the Company and each of Timothy W. Trost, Chief Financial Officer of the Company, and Dr. Randi Isaacs, M.D., Chief Medical Officer of the Company, agreed that Mr. Trost and Dr. Isaacs would resign as Chief Financial… Filing
- Feb 6, 2026ListingWerewolf Therapeutics, Inc. received a deficiency letter from the Listing Qualifications Department of the Nasdaq Stock Market, LLC notifying the Company that, for the last 30 consecutive business days, the bid price for the Company’s common stock had closed below $1.00 per share, which is the… Filing
- Dec 18, 2025AnnouncementWerewolf Therapeutics, Inc. issued a press release announcing a pipeline update, including a review of recent data for its INDUKINE ™ programs, and a business overview of its priorities for 2026 that includes a focus on the Company’s highly differentiated INDUCER T-cell engager platform. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Werewolf Therapeutics financials
Famous investors that hold HOWL
2 of the 50 well-known investors we track reported holding HOWL in their latest 13F filing. The largest position is Ken Griffin's, worth $511K.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 553,702 | $511K | 0.0% | New |
| Jim Simons · Renaissance Technologies | Q3 2026 | 550,935 | $508K | 0.0% | -18% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named HOWL in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G | 6.3% |
| Nov 16, 2026 | BALYASNY ASSET MANAGEMENT L.P. | 13G | 6.3% |
Questions about Werewolf Therapeutics, Inc. (HOWL) stock
Are HOWL insiders buying or selling?
In the last 12 months, HOWL insiders reported no open-market purchases and 105 sales worth $3.9M. The latest trade was on Jul 7, 2026. See every trade.
What is the short interest in HOWL?
As of Oct 30, 2026, 2.13M HOWL shares were sold short, 4.4% of the shares outstanding, down 9.7% from the report before. At the average daily volume of 333,048 shares, buying them all back would take about 6.4 trading days (days to cover). See the history.
Which famous investors hold HOWL?
2 of the 50 well-known investors we track reported HOWL in their latest 13F filing, including Ken Griffin, Jim Simons. The largest position is worth $511K. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.